地塞米松在门诊常见用法汇总

2018-01-12 何志超 蔡莉珊 逸仙药学V

为减轻体液潴留,除有禁忌外,所有病人在接受泰索帝(多西他赛)治疗前均必须预服药物。此类药物只能包括口服糖皮质激素类,如地塞米松,在泰索帝(多西他赛)滴注一天前服用,每天16mg(例如:每日2次,每次8mg),持续3天。(来源于CFDA说明书)

一、肿瘤科病人

1.1 多西他赛

用法:地塞米松 8mg bid d0-d2

原因:为减轻体液潴留,除有禁忌外,所有病人在接受泰索帝(多西他赛)治疗前均必须预服药物。此类药物只能包括口服糖皮质激素类,如地塞米松,在泰索帝(多西他赛)滴注一天前服用,每天16mg(例如:每日2次,每次8mg),持续3天。(来源于CFDA说明书)

原理:

多西他赛的水钠潴留包括:体液潴留包括水肿,也有报道极少数病例发生胸腔积液,腹水,心包积液,毛细血管通透性增加以及体重增加。

水钠潴留的机制与治疗处理原则:可能由于肾小球滤过率减少,肾小管对钠的重吸收增加,钠离子潴留细胞外而引起水肿。肾上腺皮质激素、抗利尿激素分泌增加,也可能是水潴留的另一个原因。由于水钠潴留,组织水肿,体重异常增加。

为何不用强的松和甲强龙呢?前两者者较长效的地塞米松而言抗炎作用弱很多,且强的松易引起水钠潴留。抗炎值分别为4.0,5.0,25.0,而钠潴留值强的松0.8,甲强龙0.5(特殊),地米为0.75。同时此外体外研究表明,多西他赛的血浆蛋白结合率超过约94~97%,地塞米松并不影响多西他赛与蛋白的结合。

1.2 紫杉醇注射液

用法:地塞米松20mg

原因:为了防止发生严重的过敏反应,接受紫杉醇的所有患者应事先进行预防用药,可采用地塞米松20mg口服,通常在用紫杉醇之前12及6小时给予,苯海拉明 (或其同类药) 50mg在泰素之前30至60分钟静注,以及在注射紫杉醇之前30-60分钟给予静脉注射西米替丁 (300mg) 或雷尼替丁(50mg)。

原理:

紫杉醇由于水溶性较差,需要加入助溶剂聚氧乙烯蓖麻油,而聚氧乙烯蓖麻油极易引起过敏性反应,紫杉醇本身易容易引起过敏,故需要使用地塞米松预防过敏。

地塞米松能够减少血液循环的T淋巴细胞、单核细胞、嗜酸性细胞,抑制巨噬细胞对抗原的摄联和处理,促使蛋白质异化,抑制蛋白质合成,影响抗体合成,达到抗过敏作用。

1.3 紫杉醇脂质体

用法:5-10mg

原因:为预防紫杉醇可能发生的过敏反应,在使用本品前30分钟,请进行以下预处理:静脉注射地塞米松5-10mg;肌肉注射苯海拉明50mg;静脉注射西米替丁300mg。

原理:紫杉醇容易引起过敏,但由于脂质体中不含聚氧乙烯蓖麻油,故预防过敏时地塞米松剂量较普通注射液低。抗过敏原理同前。

1.4 止吐(急性呕吐及迟发性呕吐)

止吐原理:地塞米松止吐机制尚不明确,但现在临床研究结果表明,地塞米松是预防急性呕吐与迟发性呕吐的有效药物。

(1)、高致吐风险

急性呕吐 12mg po or iv qd(与阿瑞匹坦联用时,6mg po or iv qd)

迟发性呕吐 8mg po or iv qd*3-4day(与阿瑞匹坦联用时,3.75mg po or iv bid*3-4day)

(2)、中致吐风险

急性呕吐 12mg po or iv qd

迟发性呕吐 8mg po or iv qd 或 4mg bid,连用2-3天

(3)、低致吐风险

迟发性呕吐 4-8mg po or iv qd*2-3天



二、皮肤科病人

2.1 带状疱疹

用法:根据《中国带状疱疹治疗指南(草稿)2013版》推荐,一般应用强的松30mg/日,折换成地塞米松4.5mg/日,疗程7天。

原因:在带状疱疹急性发作早期的治疗中,系统应用大剂量糖皮质激素可以抑制炎症过程,缩短急性疼痛的持续时间和皮损愈合时间,但对慢性疼痛(PHN)基本无效。

原理:在各种急性炎症的早期,应用糖皮质激素可减轻炎症早期的渗出、水肿、毛细血管扩张、白细胞浸润和吞噬等反应,从而改善炎症早期出现的红、肿、热、痛等临床症状;在炎症后期,应用糖皮质激素可抑制从毛细血管和成纤维细胞的增生,抑制胶原蛋白、粘多糖的合成及肉芽组织增生,从而防止炎症后期的粘连和瘢痕形成,减轻炎症的后遗症。

2.2 荨麻疹

用法:根据《中国荨麻疹诊疗指南(2014版)》推荐,糖皮质激素推荐用于急性、重症或伴有喉头水肿的荨麻疹,一般应用强的松30~40mg/日,折换成地塞米松4.5~6mg/日,疗程4~5天。

原因:荨麻疹的发病机制至今尚不十分清楚,可能涉及感染、变态反应、假变态反应和自身反应性等。肥大细胞在发病中起中心作用,其活化并脱颗粒,导致组胺、白三烯、前列腺素等释放,是影响荨麻疹发生、发展、预后和治疗反应的关键。

原理:糖皮质激素对免疫反应有多方面的抑制作用,能缓解许多过敏性疾病的症状,抑制因过敏反应而产生的病理变化。

2.3 过敏性皮炎

用法:根据《国家基本药物临床应用指南》过敏性皮炎一节推荐,重症患者应及时足量使用糖皮质激素,如氢化可的松一日200~500mg,折换成地塞米松一日7.5~18.75mg,分次静脉滴注。并依据病情变化逐步调整,逐渐减量。

原因:过敏性皮炎是由于接触过敏性抗原引起的皮肤过敏反应,它主要是由IgE介导的I型变态反应。过敏体质在首次接触过敏原时,会产生相应的抗体,抗体固定于皮肤、黏膜组织中,当再次遇到同样的过敏原,则导致肥大细胞、嗜碱细胞脱颗粒,释放组胺、5—羟色胺等过敏反应介质,即发生过敏。

原理:地塞米松能够减少血液循环的T淋巴细胞、单核细胞、嗜酸性细胞,抑制巨噬细胞对抗原的摄联和处理,促使蛋白质异化,抑制蛋白质合成,影响抗体合成,达到抗过敏作用。

2.4 接触性皮炎

用法:根据《接触性皮炎临床路径(2016版)》推荐,发生接触性皮炎,当皮损面积较大、和/或局部糜烂渗出明显、和/或出现全身系统症状时,可予中小剂量糖皮质激素(0.5-1mg/d/kg)待病情控制后可迅速减量,一般用药时间不超过7天。

原因:接触性皮炎为典型的接触性迟发型超敏反应,属于ⅳ型超敏反应,通常是由于接触小分子半抗原物质,如油漆、燃料、农药、化妆品和某些药物(磺胺和青霉素)等引起,小分子的半抗原与体内蛋白质结合成完全抗原,经朗格汉斯细胞摄取并提呈给T细胞,使其活化、分化为效应T细胞,机体再次接触相应抗原可发生接触性皮炎,导致局部皮肤出现红肿、皮疹、水疱,严重者可出现剥脱性皮炎。是一种抗原诱导的T细胞免疫应答。

机制:糖皮质激素能够减少血液循环的T淋巴细胞、单核细胞、嗜酸性细胞,抑制巨噬细胞对抗原的摄联和处理,促使蛋白质异化,抑制蛋白质合成,影响抗体合成,达到抗过敏作用,从而能缓解许多过敏性疾病的症状,抑制因过敏反应而产生的病理变化。

2.5 湿疹

用法用量:根据《中国湿疹诊疗指南(2011)》推荐,糖皮质激素在湿疹中主要用于外用,根据皮损性质选择合适强度的糖皮质激素。强效糖皮质激素连续应用一般不超过2周。1个手面积皮肤表面需要0.5个FTU,即0.25g软膏。系统治疗一般不主张常规使用。但可用于病因明确、短期可以祛除病因的患者,如接触因素、药物因素引起者或自身敏感性皮炎等。

原因:湿疹主要是由复杂的内外激发因子引起的一种迟发型变态反应。

原理:糖皮质激素能够减少血液循环的T淋巴细胞、单核细胞、嗜酸性细胞,抑制巨噬细胞对抗原的摄联和处理,促使蛋白质异化,抑制蛋白质合成,影响抗体合成,达到抗过敏作用,从而能缓解许多过敏性疾病的症状,抑制因过敏反应而产生的病理变化。

2.6 溢脂性皮炎

用法:根据《国家基本药物临床应用指南》溢脂性皮炎一节推荐,糖皮质激素一般外用,必要时可用于重症患者。

原因:溢脂性皮炎主要与激素分泌、过敏体质、精神紧张、卫生习惯、螨虫及微生物感染及其代谢产物的变态反应引起的变应性炎症,以及理化刺激等有关。

原理:应用糖皮质激素可抑制从毛细血管和成纤维细胞的增生,抑制胶原蛋白、粘多糖的合成及肉芽组织增生,从而防止炎症后期的粘连和瘢痕形成,减轻炎症的后遗症。

糖皮质激素能够减少血液循环的T淋巴细胞、单核细胞、嗜酸性细胞,抑制巨噬细胞对抗原的摄联和处理,促使蛋白质异化,抑制蛋白质合成,影响抗体合成,达到抗过敏作用,从而能缓解许多过敏性疾病的症状,抑制因过敏反应而产生的病理变化。

2.7 痤疮

用法:根据《寻常痤疮临床路径(2016版)》推荐,糖皮质激素主要用于严重的结节囊肿性痤疮、暴发性痤疮或聚合性痤疮的病情进展期,多采用小剂量(泼尼松小于15mg/天,折换成地塞米松小于2.25mg/天)短期使用。也可结节和(或)囊肿内注射糖皮质激素。

原因:痤疮是一种由多因素综合作用所致的毛囊皮脂腺疾病,其病因及发病机制包括4个方面:1)皮脂分泌增加;2)毛囊皮脂腺导管过度角化;3)毛囊皮脂腺内痤疮丙酸杆菌繁殖增加;4)在炎症介质等的作用下出现炎症反应。

原理:在各种急性炎症的早期,应用糖皮质激素可减轻炎症早期的渗出、水肿、毛细血管扩张、白细胞浸润和吞噬等反应,从而改善炎症早期出现的红、肿、热、痛等临床症状;在炎症后期,应用糖皮质激素可抑制从毛细血管和成纤维细胞的增生,抑制胶原蛋白、粘多糖的合成及肉芽组织增生,从而防止炎症后期的粘连和瘢痕形成,减轻炎症的后遗症。

2.8 隐翅虫皮炎

用法:根据《隐翅虫简介及隐翅虫皮炎发生与预防》一文推荐,糖皮质激素可小量、短期用于皮疹广泛或合并有发热等其他症状的隐翅虫皮炎。可按急性、亚急性和慢性皮炎的治疗原则处理。

原因:隐翅虫虫体内含有一种强酸性(pH 1~2)毒液,当人体拍打将虫体击伤,毒液污染皮肤,即可引起急性皮炎,疼痛剧烈,重者可出现全身反应。

原理:应用糖皮质激素可抑制从毛细血管和成纤维细胞的增生,抑制胶原蛋白、粘多糖的合成及肉芽组织增生,从而防止炎症后期的粘连和瘢痕形成,减轻炎症的后遗症。

糖皮质激素能够减少血液循环的T淋巴细胞、单核细胞、嗜酸性细胞,抑制巨噬细胞对抗原的摄联和处理,促使蛋白质异化,抑制蛋白质合成,影响抗体合成,达到抗过敏作用,从而能缓解许多过敏性疾病的症状,抑制因过敏反应而产生的病理变化。

2.9 皮肌炎

用法:根据《多发性肌炎和皮肌炎诊断及治疗指南》推荐,糖皮质激素治疗PM和DM的首选药,一般开始剂量为强的松60~100mg/天,折换成地塞米松9~15mg/天。常在用药1~2月后症状开始改善,然后开始逐渐减量。

原因:皮肌炎(DM)和多发性肌炎(PM)都属于特发性炎症性肌病(IIM),其共同特点是病因不明的慢性肌肉炎症以及由此而产生的肌无力症状,DM还有其特征性的皮肤损害。与大多数自身免疫性疾病一样,DM与PM的发病是具有遗传易感性的个体在环境因素的作用下引起的。

原理:应用糖皮质激素可抑制从毛细血管和成纤维细胞的增生,抑制胶原蛋白、粘多糖的合成及肉芽组织增生,从而防止炎症后期的粘连和瘢痕形成,减轻炎症的后遗症。

糖皮质激素能够减少血液循环的T淋巴细胞、单核细胞、嗜酸性细胞,抑制巨噬细胞对抗原的摄联和处理,促使蛋白质异化,抑制蛋白质合成,影响抗体合成,达到抗过敏作用,从而能缓解许多过敏性疾病的症状,抑制因过敏反应而产生的病理变化。

2.10 盘状红斑狼疮

用法:根据《皮肤型红斑狼疮诊疗指南(2012版)》推荐,糖皮质激素一般选用中小剂量,如泼尼松0.5 mg/(kg?d),折换成地塞米松0.075mg/(kg?d),病情控制后缓慢递减。

原因:红斑狼疮(LE)是一种典型的自身免疫性结缔组织病。在遗传因素、环境因素、雌激素水平等各种因素相互作用下,导致T淋巴细胞减少、T抑制细胞功能降低、B细胞过度增生,产生大量的自身抗体,并与体内相应的自身抗原结合形成相应的免疫复合物,沉积在皮肤、关节、小血管、肾小球等部位。在补体的参与下,引起急慢性炎症及组织坏死(如狼疮肾炎),或抗体直接与组织细胞抗原作用,引起细胞破坏(如红细胞、淋巴细胞及血小板壁的特异性抗原与相应的自身抗体结合,分别引起溶血性贫血、淋巴细胞减少症和血小板减少症),从而导致机体的多系统损害。

原理:应用糖皮质激素可抑制从毛细血管和成纤维细胞的增生,抑制胶原蛋白、粘多糖的合成及肉芽组织增生,从而防止炎症后期的粘连和瘢痕形成,减轻炎症的后遗症。

糖皮质激素能够减少血液循环的T淋巴细胞、单核细胞、嗜酸性细胞,抑制巨噬细胞对抗原的摄联和处理,促使蛋白质异化,抑制蛋白质合成,影响抗体合成,达到抗过敏作用,从而能缓解许多过敏性疾病的症状,抑制因过敏反应而产生的病理变化。

2.11 体癣、股癣

用法用量:根据《体股癣诊疗指南(2008版)》推荐,糖皮质激素一般外用,可用于炎症较严重的体股癣患者,限期1~2周。

原因:体股癣的主要病原菌为红色毛癣菌和须癣毛癣菌。一旦感染建立,毛癣菌和须癣毛癣菌的生长速度和表皮更新速度对于损害的发展是两个关键性因素。前者必须相等或前者大于后者,否则毛癣菌和须癣毛癣菌数量将下降。毛癣菌和须癣毛癣菌所产生的角蛋白酶和其他蛋白分解酶,不仅与其在皮肤定植和侵入,而且表现为皮肤损害。

原理:在各种急性炎症的早期,应用糖皮质激素可减轻炎症早期的渗出、水肿、毛细血管扩张、白细胞浸润和吞噬等反应,从而改善炎症早期出现的红、肿、热、痛等临床症状;在炎症后期,应用糖皮质激素可抑制从毛细血管和成纤维细胞的增生,抑制胶原蛋白、粘多糖的合成及肉芽组织增生,从而防止炎症后期的粘连和瘢痕形成,减轻炎症的后遗症。

三 口腔科病人

3.1 牙髓炎、牙周炎

用法:根据《实用牙髓病诊疗学》推荐,一般应用强的松10mg,折换成地塞米松0.75mg,每日三次。预防或治疗炎症反应一般只需1~2天。

原因:牙髓因受到病源刺激物的作用不同以及机体抵抗力的差异,出现不同的病理变化。由于牙髓组织是处于四壁坚硬缺乏弹性的牙髓腔中,其血液循环只能通过细小的根尖孔,缺乏侧枝循环,一旦牙髓发生炎症,炎症渗出物不易引流,髓腔内压很快增高,产生剧烈疼痛。

原理:应用糖皮质激素可减轻炎症早期的渗出、水肿、毛细血管扩张、白细胞浸润和吞噬等反应,从而改善炎症早期出现的红、肿、热、痛等临床症状。

3.2 阻生齿

用法:糖皮质激素主要用于阻生齿拔除术,一般应用地塞米松5mg。

原因:预防阻生齿拔除术后并发症。

原理:应用糖皮质激素可减轻炎症早期的渗出、水肿、毛细血管扩张、白细胞浸润和吞噬等反应,从而改善炎症早期出现的红、肿、热、痛等临床症状。拔牙后立即用药,恰好发挥了激素的药理作用,使肿痛、张口困难有明显的缓解。

3.3 根尖周炎、根尖周脓肿

用法用量:在治疗根尖周炎、脓肿时, 可在病患患牙根尖区骨膜上局部注射地塞米松溶液,一般应用5mg。

原因:根尖周炎、根尖周脓肿是发生于牙根尖周围的局限性疼痛性炎症。治疗应开髓拔髓,开放引流,脓肿形成后应切开引流,给予消炎止痛药物;急性期症状缓解后做根管治疗术或牙髓塑化治疗。

原理:应用糖皮质激素可减轻炎症早期的渗出、水肿、毛细血管扩张、白细胞浸润和吞噬等反应,从而改善炎症早期出现的红、肿、热、痛等临床症状。可在缓解疼痛的同时,也有助于瘘管的愈合,减小炎症范围,从而有效的减少了根尖周病的治疗时长。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (17)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=278887, encodeId=9dc72e8887d0, content=学习了感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Tue Jan 16 00:34:43 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278038, encodeId=a6092e8038eb, content=非常棒.昨天还碰到类似病历, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/41paVl6MRw59My0IM7QYQFe7SXAey2UX1Lz0fiaF2ZzJiaj9HpzkoUkOcIp3yBOkJuvOqkRFfBQKiaXHrNMe8jQjQ/0, createdBy=ed5c2235197, createdName=杨sir, createdTime=Sat Jan 13 07:47:02 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277868, encodeId=f6222e786880, content=不错不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/y1ZJaAFo7AFqm7Hn2QNVTjOpBV9mRicUEjyBqRMnLADF1oQXJGeIVCpiaY1hJVMd1C40EhFCw4LL8sCKTx8Yuvsw/132, createdBy=af0b1960284, createdName=孙文杰, createdTime=Fri Jan 12 14:57:36 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277782, encodeId=d8462e778233, content=学习了很有用不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Jan 12 09:24:37 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277780, encodeId=4a752e7780af, content=厉害了.受教, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/10/81abdcda5edda088fae89d3224a342d1.jpg, createdBy=79f42243411, createdName=阳阳335788, createdTime=Fri Jan 12 09:17:56 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277779, encodeId=1f2e2e777989, content=强, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/10/81abdcda5edda088fae89d3224a342d1.jpg, createdBy=79f42243411, createdName=阳阳335788, createdTime=Fri Jan 12 09:17:46 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277777, encodeId=460b2e7777f0, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri Jan 12 09:10:25 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277760, encodeId=f6442e77608a, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Fri Jan 12 08:51:36 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277741, encodeId=1f952e7741b0, content=学习了提高了, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Fri Jan 12 08:02:20 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277736, encodeId=96ed2e773697, content=好东西.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Jan 12 07:49:31 CST 2018, time=2018-01-12, status=1, ipAttribution=)]
    2018-01-16 lofter

    学习了感谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=278887, encodeId=9dc72e8887d0, content=学习了感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Tue Jan 16 00:34:43 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278038, encodeId=a6092e8038eb, content=非常棒.昨天还碰到类似病历, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/41paVl6MRw59My0IM7QYQFe7SXAey2UX1Lz0fiaF2ZzJiaj9HpzkoUkOcIp3yBOkJuvOqkRFfBQKiaXHrNMe8jQjQ/0, createdBy=ed5c2235197, createdName=杨sir, createdTime=Sat Jan 13 07:47:02 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277868, encodeId=f6222e786880, content=不错不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/y1ZJaAFo7AFqm7Hn2QNVTjOpBV9mRicUEjyBqRMnLADF1oQXJGeIVCpiaY1hJVMd1C40EhFCw4LL8sCKTx8Yuvsw/132, createdBy=af0b1960284, createdName=孙文杰, createdTime=Fri Jan 12 14:57:36 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277782, encodeId=d8462e778233, content=学习了很有用不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Jan 12 09:24:37 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277780, encodeId=4a752e7780af, content=厉害了.受教, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/10/81abdcda5edda088fae89d3224a342d1.jpg, createdBy=79f42243411, createdName=阳阳335788, createdTime=Fri Jan 12 09:17:56 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277779, encodeId=1f2e2e777989, content=强, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/10/81abdcda5edda088fae89d3224a342d1.jpg, createdBy=79f42243411, createdName=阳阳335788, createdTime=Fri Jan 12 09:17:46 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277777, encodeId=460b2e7777f0, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri Jan 12 09:10:25 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277760, encodeId=f6442e77608a, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Fri Jan 12 08:51:36 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277741, encodeId=1f952e7741b0, content=学习了提高了, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Fri Jan 12 08:02:20 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277736, encodeId=96ed2e773697, content=好东西.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Jan 12 07:49:31 CST 2018, time=2018-01-12, status=1, ipAttribution=)]
    2018-01-13 杨sir

    非常棒.昨天还碰到类似病历

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=278887, encodeId=9dc72e8887d0, content=学习了感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Tue Jan 16 00:34:43 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278038, encodeId=a6092e8038eb, content=非常棒.昨天还碰到类似病历, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/41paVl6MRw59My0IM7QYQFe7SXAey2UX1Lz0fiaF2ZzJiaj9HpzkoUkOcIp3yBOkJuvOqkRFfBQKiaXHrNMe8jQjQ/0, createdBy=ed5c2235197, createdName=杨sir, createdTime=Sat Jan 13 07:47:02 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277868, encodeId=f6222e786880, content=不错不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/y1ZJaAFo7AFqm7Hn2QNVTjOpBV9mRicUEjyBqRMnLADF1oQXJGeIVCpiaY1hJVMd1C40EhFCw4LL8sCKTx8Yuvsw/132, createdBy=af0b1960284, createdName=孙文杰, createdTime=Fri Jan 12 14:57:36 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277782, encodeId=d8462e778233, content=学习了很有用不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Jan 12 09:24:37 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277780, encodeId=4a752e7780af, content=厉害了.受教, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/10/81abdcda5edda088fae89d3224a342d1.jpg, createdBy=79f42243411, createdName=阳阳335788, createdTime=Fri Jan 12 09:17:56 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277779, encodeId=1f2e2e777989, content=强, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/10/81abdcda5edda088fae89d3224a342d1.jpg, createdBy=79f42243411, createdName=阳阳335788, createdTime=Fri Jan 12 09:17:46 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277777, encodeId=460b2e7777f0, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri Jan 12 09:10:25 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277760, encodeId=f6442e77608a, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Fri Jan 12 08:51:36 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277741, encodeId=1f952e7741b0, content=学习了提高了, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Fri Jan 12 08:02:20 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277736, encodeId=96ed2e773697, content=好东西.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Jan 12 07:49:31 CST 2018, time=2018-01-12, status=1, ipAttribution=)]
    2018-01-12 孙文杰

    不错不错学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=278887, encodeId=9dc72e8887d0, content=学习了感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Tue Jan 16 00:34:43 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278038, encodeId=a6092e8038eb, content=非常棒.昨天还碰到类似病历, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/41paVl6MRw59My0IM7QYQFe7SXAey2UX1Lz0fiaF2ZzJiaj9HpzkoUkOcIp3yBOkJuvOqkRFfBQKiaXHrNMe8jQjQ/0, createdBy=ed5c2235197, createdName=杨sir, createdTime=Sat Jan 13 07:47:02 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277868, encodeId=f6222e786880, content=不错不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/y1ZJaAFo7AFqm7Hn2QNVTjOpBV9mRicUEjyBqRMnLADF1oQXJGeIVCpiaY1hJVMd1C40EhFCw4LL8sCKTx8Yuvsw/132, createdBy=af0b1960284, createdName=孙文杰, createdTime=Fri Jan 12 14:57:36 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277782, encodeId=d8462e778233, content=学习了很有用不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Jan 12 09:24:37 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277780, encodeId=4a752e7780af, content=厉害了.受教, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/10/81abdcda5edda088fae89d3224a342d1.jpg, createdBy=79f42243411, createdName=阳阳335788, createdTime=Fri Jan 12 09:17:56 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277779, encodeId=1f2e2e777989, content=强, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/10/81abdcda5edda088fae89d3224a342d1.jpg, createdBy=79f42243411, createdName=阳阳335788, createdTime=Fri Jan 12 09:17:46 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277777, encodeId=460b2e7777f0, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri Jan 12 09:10:25 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277760, encodeId=f6442e77608a, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Fri Jan 12 08:51:36 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277741, encodeId=1f952e7741b0, content=学习了提高了, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Fri Jan 12 08:02:20 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277736, encodeId=96ed2e773697, content=好东西.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Jan 12 07:49:31 CST 2018, time=2018-01-12, status=1, ipAttribution=)]
    2018-01-12 飛歌

    学习了很有用不错

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=278887, encodeId=9dc72e8887d0, content=学习了感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Tue Jan 16 00:34:43 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278038, encodeId=a6092e8038eb, content=非常棒.昨天还碰到类似病历, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/41paVl6MRw59My0IM7QYQFe7SXAey2UX1Lz0fiaF2ZzJiaj9HpzkoUkOcIp3yBOkJuvOqkRFfBQKiaXHrNMe8jQjQ/0, createdBy=ed5c2235197, createdName=杨sir, createdTime=Sat Jan 13 07:47:02 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277868, encodeId=f6222e786880, content=不错不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/y1ZJaAFo7AFqm7Hn2QNVTjOpBV9mRicUEjyBqRMnLADF1oQXJGeIVCpiaY1hJVMd1C40EhFCw4LL8sCKTx8Yuvsw/132, createdBy=af0b1960284, createdName=孙文杰, createdTime=Fri Jan 12 14:57:36 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277782, encodeId=d8462e778233, content=学习了很有用不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Jan 12 09:24:37 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277780, encodeId=4a752e7780af, content=厉害了.受教, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/10/81abdcda5edda088fae89d3224a342d1.jpg, createdBy=79f42243411, createdName=阳阳335788, createdTime=Fri Jan 12 09:17:56 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277779, encodeId=1f2e2e777989, content=强, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/10/81abdcda5edda088fae89d3224a342d1.jpg, createdBy=79f42243411, createdName=阳阳335788, createdTime=Fri Jan 12 09:17:46 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277777, encodeId=460b2e7777f0, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri Jan 12 09:10:25 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277760, encodeId=f6442e77608a, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Fri Jan 12 08:51:36 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277741, encodeId=1f952e7741b0, content=学习了提高了, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Fri Jan 12 08:02:20 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277736, encodeId=96ed2e773697, content=好东西.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Jan 12 07:49:31 CST 2018, time=2018-01-12, status=1, ipAttribution=)]
    2018-01-12 阳阳335788

    厉害了.受教

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=278887, encodeId=9dc72e8887d0, content=学习了感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Tue Jan 16 00:34:43 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278038, encodeId=a6092e8038eb, content=非常棒.昨天还碰到类似病历, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/41paVl6MRw59My0IM7QYQFe7SXAey2UX1Lz0fiaF2ZzJiaj9HpzkoUkOcIp3yBOkJuvOqkRFfBQKiaXHrNMe8jQjQ/0, createdBy=ed5c2235197, createdName=杨sir, createdTime=Sat Jan 13 07:47:02 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277868, encodeId=f6222e786880, content=不错不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/y1ZJaAFo7AFqm7Hn2QNVTjOpBV9mRicUEjyBqRMnLADF1oQXJGeIVCpiaY1hJVMd1C40EhFCw4LL8sCKTx8Yuvsw/132, createdBy=af0b1960284, createdName=孙文杰, createdTime=Fri Jan 12 14:57:36 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277782, encodeId=d8462e778233, content=学习了很有用不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Jan 12 09:24:37 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277780, encodeId=4a752e7780af, content=厉害了.受教, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/10/81abdcda5edda088fae89d3224a342d1.jpg, createdBy=79f42243411, createdName=阳阳335788, createdTime=Fri Jan 12 09:17:56 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277779, encodeId=1f2e2e777989, content=强, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/10/81abdcda5edda088fae89d3224a342d1.jpg, createdBy=79f42243411, createdName=阳阳335788, createdTime=Fri Jan 12 09:17:46 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277777, encodeId=460b2e7777f0, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri Jan 12 09:10:25 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277760, encodeId=f6442e77608a, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Fri Jan 12 08:51:36 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277741, encodeId=1f952e7741b0, content=学习了提高了, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Fri Jan 12 08:02:20 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277736, encodeId=96ed2e773697, content=好东西.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Jan 12 07:49:31 CST 2018, time=2018-01-12, status=1, ipAttribution=)]
    2018-01-12 阳阳335788

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=278887, encodeId=9dc72e8887d0, content=学习了感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Tue Jan 16 00:34:43 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278038, encodeId=a6092e8038eb, content=非常棒.昨天还碰到类似病历, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/41paVl6MRw59My0IM7QYQFe7SXAey2UX1Lz0fiaF2ZzJiaj9HpzkoUkOcIp3yBOkJuvOqkRFfBQKiaXHrNMe8jQjQ/0, createdBy=ed5c2235197, createdName=杨sir, createdTime=Sat Jan 13 07:47:02 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277868, encodeId=f6222e786880, content=不错不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/y1ZJaAFo7AFqm7Hn2QNVTjOpBV9mRicUEjyBqRMnLADF1oQXJGeIVCpiaY1hJVMd1C40EhFCw4LL8sCKTx8Yuvsw/132, createdBy=af0b1960284, createdName=孙文杰, createdTime=Fri Jan 12 14:57:36 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277782, encodeId=d8462e778233, content=学习了很有用不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Jan 12 09:24:37 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277780, encodeId=4a752e7780af, content=厉害了.受教, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/10/81abdcda5edda088fae89d3224a342d1.jpg, createdBy=79f42243411, createdName=阳阳335788, createdTime=Fri Jan 12 09:17:56 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277779, encodeId=1f2e2e777989, content=强, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/10/81abdcda5edda088fae89d3224a342d1.jpg, createdBy=79f42243411, createdName=阳阳335788, createdTime=Fri Jan 12 09:17:46 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277777, encodeId=460b2e7777f0, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri Jan 12 09:10:25 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277760, encodeId=f6442e77608a, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Fri Jan 12 08:51:36 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277741, encodeId=1f952e7741b0, content=学习了提高了, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Fri Jan 12 08:02:20 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277736, encodeId=96ed2e773697, content=好东西.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Jan 12 07:49:31 CST 2018, time=2018-01-12, status=1, ipAttribution=)]
    2018-01-12 龙胆草

    学习谢谢分享

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=278887, encodeId=9dc72e8887d0, content=学习了感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Tue Jan 16 00:34:43 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278038, encodeId=a6092e8038eb, content=非常棒.昨天还碰到类似病历, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/41paVl6MRw59My0IM7QYQFe7SXAey2UX1Lz0fiaF2ZzJiaj9HpzkoUkOcIp3yBOkJuvOqkRFfBQKiaXHrNMe8jQjQ/0, createdBy=ed5c2235197, createdName=杨sir, createdTime=Sat Jan 13 07:47:02 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277868, encodeId=f6222e786880, content=不错不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/y1ZJaAFo7AFqm7Hn2QNVTjOpBV9mRicUEjyBqRMnLADF1oQXJGeIVCpiaY1hJVMd1C40EhFCw4LL8sCKTx8Yuvsw/132, createdBy=af0b1960284, createdName=孙文杰, createdTime=Fri Jan 12 14:57:36 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277782, encodeId=d8462e778233, content=学习了很有用不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Jan 12 09:24:37 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277780, encodeId=4a752e7780af, content=厉害了.受教, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/10/81abdcda5edda088fae89d3224a342d1.jpg, createdBy=79f42243411, createdName=阳阳335788, createdTime=Fri Jan 12 09:17:56 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277779, encodeId=1f2e2e777989, content=强, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/10/81abdcda5edda088fae89d3224a342d1.jpg, createdBy=79f42243411, createdName=阳阳335788, createdTime=Fri Jan 12 09:17:46 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277777, encodeId=460b2e7777f0, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri Jan 12 09:10:25 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277760, encodeId=f6442e77608a, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Fri Jan 12 08:51:36 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277741, encodeId=1f952e7741b0, content=学习了提高了, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Fri Jan 12 08:02:20 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277736, encodeId=96ed2e773697, content=好东西.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Jan 12 07:49:31 CST 2018, time=2018-01-12, status=1, ipAttribution=)]
    2018-01-12 明月清辉

    谢谢分享.学习了

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=278887, encodeId=9dc72e8887d0, content=学习了感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Tue Jan 16 00:34:43 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278038, encodeId=a6092e8038eb, content=非常棒.昨天还碰到类似病历, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/41paVl6MRw59My0IM7QYQFe7SXAey2UX1Lz0fiaF2ZzJiaj9HpzkoUkOcIp3yBOkJuvOqkRFfBQKiaXHrNMe8jQjQ/0, createdBy=ed5c2235197, createdName=杨sir, createdTime=Sat Jan 13 07:47:02 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277868, encodeId=f6222e786880, content=不错不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/y1ZJaAFo7AFqm7Hn2QNVTjOpBV9mRicUEjyBqRMnLADF1oQXJGeIVCpiaY1hJVMd1C40EhFCw4LL8sCKTx8Yuvsw/132, createdBy=af0b1960284, createdName=孙文杰, createdTime=Fri Jan 12 14:57:36 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277782, encodeId=d8462e778233, content=学习了很有用不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Jan 12 09:24:37 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277780, encodeId=4a752e7780af, content=厉害了.受教, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/10/81abdcda5edda088fae89d3224a342d1.jpg, createdBy=79f42243411, createdName=阳阳335788, createdTime=Fri Jan 12 09:17:56 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277779, encodeId=1f2e2e777989, content=强, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/10/81abdcda5edda088fae89d3224a342d1.jpg, createdBy=79f42243411, createdName=阳阳335788, createdTime=Fri Jan 12 09:17:46 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277777, encodeId=460b2e7777f0, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri Jan 12 09:10:25 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277760, encodeId=f6442e77608a, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Fri Jan 12 08:51:36 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277741, encodeId=1f952e7741b0, content=学习了提高了, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Fri Jan 12 08:02:20 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277736, encodeId=96ed2e773697, content=好东西.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Jan 12 07:49:31 CST 2018, time=2018-01-12, status=1, ipAttribution=)]
    2018-01-12 杨利洪

    学习了提高了

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=278887, encodeId=9dc72e8887d0, content=学习了感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Tue Jan 16 00:34:43 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278038, encodeId=a6092e8038eb, content=非常棒.昨天还碰到类似病历, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/41paVl6MRw59My0IM7QYQFe7SXAey2UX1Lz0fiaF2ZzJiaj9HpzkoUkOcIp3yBOkJuvOqkRFfBQKiaXHrNMe8jQjQ/0, createdBy=ed5c2235197, createdName=杨sir, createdTime=Sat Jan 13 07:47:02 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277868, encodeId=f6222e786880, content=不错不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/y1ZJaAFo7AFqm7Hn2QNVTjOpBV9mRicUEjyBqRMnLADF1oQXJGeIVCpiaY1hJVMd1C40EhFCw4LL8sCKTx8Yuvsw/132, createdBy=af0b1960284, createdName=孙文杰, createdTime=Fri Jan 12 14:57:36 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277782, encodeId=d8462e778233, content=学习了很有用不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Jan 12 09:24:37 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277780, encodeId=4a752e7780af, content=厉害了.受教, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/10/81abdcda5edda088fae89d3224a342d1.jpg, createdBy=79f42243411, createdName=阳阳335788, createdTime=Fri Jan 12 09:17:56 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277779, encodeId=1f2e2e777989, content=强, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/10/81abdcda5edda088fae89d3224a342d1.jpg, createdBy=79f42243411, createdName=阳阳335788, createdTime=Fri Jan 12 09:17:46 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277777, encodeId=460b2e7777f0, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri Jan 12 09:10:25 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277760, encodeId=f6442e77608a, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Fri Jan 12 08:51:36 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277741, encodeId=1f952e7741b0, content=学习了提高了, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Fri Jan 12 08:02:20 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277736, encodeId=96ed2e773697, content=好东西.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Jan 12 07:49:31 CST 2018, time=2018-01-12, status=1, ipAttribution=)]
    2018-01-12 天地飞扬

    好东西.谢谢分享!

    0

相关资讯

Blood:依托泊苷联合地塞米松用于淋巴组织细胞增生症的效果:HLH-2004长期研究的结果。

淋巴组织细胞增生症(HLH)是一种危及生命的超炎症综合征,包括家族/遗传HLH(FHL)和继发性HLH。

J Clin Anesth:静脉注射地塞米松作为改善分娩镇痛的辅助:随机、双盲、安慰剂对照试验

研究静脉注射(i.v.)地塞米松作为辅助分娩镇痛中的作用。

EUR J Cancer:使用环磷酰胺 - 硼替佐米 - 地塞米松治疗原发性轻链型心脏淀粉样变性中地塞米松的心脏毒性

非骨髓瘤浆细胞恶液质疾病泛指骨髓瘤以外因浆细胞增生所产生的病症。包括单克隆伽玛球蛋白症(monoclonal gammopathy of undeterminated significance;MGUS),轻链型淀粉样变性(light-chain related amyloidosis),冷凝球蛋白血症(cryoglobulinemia)等。

Iran J Otorhinolaryngol:突发性感官听力损失中鼓膜内地塞米松-透明质酸治疗作用分析

听力损失是一种常见的疾病,通常通过全身用药和/或者鼓膜内注射皮质类固醇来进行治疗。最近,有研究人员比较了鼓膜内注射地塞米松以及与透明质酸结合注射时,对突发性感官听力损失病人的治疗效应。在该次临床实践中,40名病人被随机分配到2个组;在第一个小组中,20名病人接受2.4毫克鼓膜内地塞米松注射,然而在第二小组中,病人接受2.4毫克地塞米松和2毫克透明质酸组合注射。两个小组的病人每隔一天进行一次注射,总

Retina: 玻璃体腔内注射地塞米松的位置与眼高压相关性研究

印度巴罗达Sudhalkar眼科医院和视网膜中心的Sudhalkar A近日在Retina杂志上发表了他们近期的一项工作,他们研究了玻璃体腔内注射地塞米松的位置与眼高压(OHT)之间的关系。

CLIN CANCER RES:Ricolinostat联合硼替佐米以及地塞米松治疗复发或难治性多发性骨髓瘤

抑制组蛋白脱乙酰基酶(HDAC)可以增强蛋白酶体抑制作用治疗多发性骨髓瘤的疗效,但是也会增加毒性。临床前研究发现HDAC6通过蛋白质降解过程中的聚集体/自噬途径调节蛋白体酶抑制抵抗。CLIN CANCER RES近期发表了一篇文章,报道HDAC6选择性抑制剂Ricolinostat的临床试验结果。